Would you wait to treat a ground glass opacity lesion (minimally invasive adenocarcinoma or adenocarcnioma in situ) with SBRT until there is more of a solid component?

In general, it is understood that the appropriate indication for utilizing lung SBRT is in the setting of a diagnosis of invasive cancer, i.e., early stage lung cancer or an oligometastatic lesion. With regard to ground glass opacities (GGOs) it is understood that the differential for these entities...